Farallon Capital Management has established a new, significant stake in biotechnology firm Exelixis (EXEL). According to its latest 13F filing, the investment firm acquired 13.11 million shares, creating a position valued at approximately $562.33 million. This new holding now constitutes 3.21% of Farallon's reported portfolio.
This disclosure was made in a quarterly report filed on August 14, 2026, which reflects holdings as of March 31, 2026. Therefore, the trades took place during the first quarter of the year. During that period, Exelixis reported strong financial results, beating analyst expectations for revenue and earnings per share. The company also continued a significant stock repurchase program.